查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088365

自體幹細胞和非幹細胞療法市場：2026-2032年全球市場預測（依療法類型、適應症、細胞來源、給藥途徑、處理程度和最終用戶分類）

Autologous Stem Cell & Non-Stem Cell Therapies Market by Therapy Type, Indication, Cell Source, Administration Route, Manipulation Level, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，自體幹細胞和非幹細胞療法市場將成長至 180.1 億美元，複合年成長率為 16.23%。

主要市場統計數據
基準年 2025 62.8億美元
預計年份：2026年 72.7億美元
預測年份 2032 180.1億美元
複合年成長率 (%) 16.23%

自體幹細胞和非幹細胞療法利用患者自身的細胞來修復組織、恢復免疫功能或標靶治療疾病，從而降低與捐贈者相容性和移植物抗宿主疾病相關的風險。此類療法包括成熟的自體造血幹細胞移植、快速發展的CAR-T細胞療法、腫瘤浸潤淋巴細胞療法、自體細胞再生醫學、富血小板血漿（PRP）療法、軟骨細胞移植等個人化細胞療法。

市場發展動能主要受腫瘤學和血液學領域已證實有效的臨床應用、肌肉骨骼疾病和自體免疫疾病適應症方面不斷擴大的證據，以及先進醫療產品和人類細胞、組織及細胞/組織衍生產品的監管途徑所驅動。就相關性而言，需求最強的徵兆集中在自體細胞療法、個人化再生醫學、CAR-T細胞生產、幹細胞移植、細胞處理、細胞療法供應鏈以及即時檢測（PoC）細胞療法平台。

治療方式的變革性改變。

治療格局正從以流程主導的細胞採集轉向標準化、數位化控制的封閉式系統生產。醫院、合約研發生產機構 (CDMO) 和生物製藥贊助商正在投資整合自動化白血球分離方法、冷凍保存、身分管理系統、儲存歷史追蹤和交付前檢測，旨在縮短個人化治療的「投資回報週期」。

人工智慧（AI）的累積影響

人工智慧（AI）正成為自體幹細胞和非幹細胞療法整體發展的重要驅動力。 AI驅動的影像分析、多組體學分析和預測分析正在為患者篩選、療效評估、藥物釋放決策和不利事件監測提供支持，尤其是在細胞表現型和功能活性影響治療結果的複雜免疫療法中。

對關鍵區域的洞察

亞太地區自體細胞療法正經歷高速成長，這得益於日本的再生醫學體系、中國不斷擴大的臨床試驗基礎、韓國的生物技術實力、印度注重成本效益的醫院網路以及澳大利亞強大的轉化研究基礎設施。該地區對腫瘤中心、移植計畫、再生醫學實驗室以及整合了生產能力和臨床管治的細胞處理設施的需求最為旺盛。

關鍵的群體特定見解

東協市場正透過醫療旅遊、癌症中心的擴張以及人們對再生醫學日益成長的興趣而發展，儘管各成員國的監管成熟度和品管的嚴謹程度有所不同。海灣合作理事會（GCC）國家正在投資三級醫療、移植服務、國家基因組計劃和精準醫療項目，這些都有助於自體療法的有序引入。在專科醫院和國際臨床合作不斷拓展的地區，這一趨勢尤其顯著。

主要國家的概況

美國在自體免疫療法的商業性化推廣方面處於主導地位，這得益於FDA的批准、大型癌症中心、獲得認證的細胞治療項目以及強大的生產生態系統。在加拿大，移植和腫瘤治療網路正穩步推進自體免疫療法的應用。同時，墨西哥作為區域准入中心正日益受到關注，前提是相關療法能夠滿足嚴格的安全、倫理和品質標準。巴西在拉丁美洲擁有最強大的基礎，這體現在臨床研究規模、血液學專業知識以及公共和私人醫療保健需求等。

為行業領導者提供的實用建議

行業領導者應優先考慮提供證據，將臨床結果與可生產性、每次治療成功成本、啟動時間以及長期安全性聯繫起來。完善的註冊登記系統、真實世界數據 (RWE) 項目、標準化的不利事件追蹤以及統一的療效檢測法可以增強支付方的信心，並加速自體細胞療法的廣泛應用。

調查方法

本執行摘要基於二手研究，資訊來自監管機構、同行評審文獻、臨床試驗註冊庫、臨床實踐指南、醫院應用趨勢以及細胞治療、移植和再生醫學相關機構的公開資料。摘要著重於檢驗的市場趨勢、已通過核准的治療方案和成熟的基礎設施建設，而非未經證實的說法。

結論

自體和非幹細胞療法正從專業的臨床操作發展成為一個更結構化的個人化醫療市場。當患者特異性的生物學特徵、持續的療效、可控的生產過程和完善的臨床監測相結合時，它們的價值提案才能發揮到極致。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：自體幹細胞與非幹細胞療法市場：依療法類型分類

  • 非幹細胞療法
    • 外泌體
    • 富血小板血漿
      • 白血球去除富血小板血漿
      • 白血球富集 PRP
    • 基質血管成分
  • 幹細胞療法
    • 造血幹細胞
      • 骨髓來源的
      • 源自臍帶血
      • 周邊血來源
    • 誘導性多功能細胞
    • 間質幹細胞
      • 源自脂肪組織
      • 骨髓來源的
      • 臍帶起源

第8章：自體幹細胞與非幹細胞療法市場：依適應症分類

  • 心血管系統
    • 缺血性心臟疾病
    • 心肌梗塞
    • 周邊動脈疾病
  • 皮膚科
    • 毛髮再生
    • 活膚
    • 創傷治療
  • 神經病學
    • 神經退化性疾病
    • 脊髓損傷
    • 中風
  • 整形外科
    • 骨缺損
    • 軟骨修復
    • 骨關節炎
    • 肌腱損傷
  • 風濕病學
    • 骨關節炎
    • 銀屑病
    • 類風濕性關節炎

第9章：自體幹細胞與非幹細胞治療市場：依細胞來源分類

  • 脂肪組織
  • 骨髓
  • 周邊血
  • 臍帶
    • 臍帶血
    • 沃頓氏膠

第10章：自體幹細胞與非幹細胞療法市場：依給藥途徑分類

  • 關節內給藥
    • 髖關節
    • 膝關節
    • 肩關節
  • 皮內給藥
  • 肌肉內部
  • 靜脈
    • 周邊注射
    • 門靜脈注射
  • 皮下

第11章：自體幹細胞與非幹細胞治療市場：依營運層面分類

  • 進階操作
    • 文化與成長
    • 基因改造
  • 最低限度操作

第12章：自體幹細胞與非幹細胞治療市場：依最終使用者分類

  • 門診手術中心
  • 診所
    • 循環系統診所
    • 美容診所
    • 整形外科診所
  • 醫院
  • 研究機構
    • 學術機構
    • 政府研究機構
    • 私人研究機構

第13章：自體幹細胞與非幹細胞療法市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：自體幹細胞與非幹細胞治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：自體幹細胞與非幹細胞療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Anterogen Co., Ltd.
  • Bluebird Bio, Inc.
  • Brainstorm Cell Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Cambium Bio Limited
  • Castle Creek Biosciences Inc.
  • Cytori Therapeutics Inc.
  • Dendreon Pharmaceuticals LLC
  • Gilead Sciences, Inc.
  • Globus Medical Inc
  • HCA International Limited
  • Hemogenyx Pharmaceuticals PLC
  • Hemostemix Inc.
  • Jasper Therapeutics, Inc.
  • Juventas Therapeutics, Inc.
  • Kolon TissueGene, Inc.
  • Lisata Therapeutics, Inc.
  • Medipost Co., Ltd.
  • NOVADIP Biosciences SA
  • Novartis AG
  • Stempeutics Research Pvt. Ltd.
  • Vericel Corporation
Product Code: MRR-030C42D3EDB5

The Autologous Stem Cell & Non-Stem Cell Therapies Market is projected to grow by USD 18.01 billion at a CAGR of 16.23% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.28 billion
Estimated Year [2026] USD 7.27 billion
Forecast Year [2032] USD 18.01 billion
CAGR (%) 16.23%

Autologous stem cell and non-stem cell therapies use a patient's own cells to repair tissue, restore immune function, or target disease, reducing risks linked to donor matching and graft-versus-host disease. The category includes established procedures such as autologous hematopoietic stem cell transplantation, rapidly advancing CAR-T cell therapy, tumor-infiltrating lymphocyte therapy, autologous cell-based regenerative medicine, platelet-rich plasma, chondrocyte implantation, and other personalized cellular interventions.

Market momentum is being shaped by validated clinical adoption in oncology and hematology, expanding evidence in musculoskeletal and autoimmune indications, and regulatory pathways for advanced therapy medicinal products and human cells, tissues, and cellular and tissue-based products. For relevance, the strongest demand signals are concentrated around autologous cell therapy, personalized regenerative medicine, CAR-T manufacturing, stem cell transplantation, cell processing, cell therapy supply chain, and point-of-care cell therapy platforms.

Transformative Shifts in the Therapy Landscape

The landscape is shifting from procedure-led cell harvesting toward standardized, digitally controlled, and closed-system manufacturing. Hospitals, contract development and manufacturing organizations, and biopharma sponsors are investing in automated leukapheresis integration, cryopreservation, chain-of-identity systems, chain-of-custody controls, and release testing designed to shorten vein-to-vein time for patient-specific therapies.

Clinical strategy is also changing. Autologous therapies are moving beyond late-line oncology into earlier treatment settings where durable response, lower relapse risk, and real-world evidence can support stronger clinical value. At the same time, cost, scalability, reimbursement, sterility assurance, manufacturing consistency, and patient eligibility remain key barriers that shape commercial success.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across autologous stem cell and non-stem cell therapy development. AI-driven image analysis, multi-omics interpretation, and predictive analytics support patient selection, potency assessment, release decision support, and adverse event monitoring, especially in complex immunotherapies where cell phenotype and functional activity influence outcomes.

In manufacturing, AI can support batch-failure prediction, process parameter optimization, automated quality review, deviation detection, and logistics forecasting. These applications are most valuable when paired with validated data governance, Good Manufacturing Practice controls, secure patient data handling, bias monitoring, and explainable models that regulators and clinicians can audit.

Key Regional Insights

Asia-Pacific is a high-growth region for autologous cell therapies, supported by Japan's regenerative medicine framework, China's expanding clinical trial base, South Korea's biotechnology capabilities, India's cost-sensitive hospital networks, and Australia's strong translational research infrastructure. Demand is strongest where oncology centers, transplant programs, regenerative medicine institutes, and cell processing facilities are integrated with manufacturing capacity and clinical governance.

North America remains the most commercially mature region, led by the United States through FDA-regulated cell and gene therapy approvals, advanced academic medical centers, accredited transplant programs, and specialized reimbursement models. Canada contributes through regulated stem cell transplantation networks and clinical research capacity. Latin America shows selective growth through Brazil and Mexico, where oncology access, private hospital systems, and regulatory oversight influence adoption. Europe benefits from the European Medicines Agency's advanced therapy framework and strong clinical centers in Germany, France, Italy, Spain, and the United Kingdom. The Middle East is gaining traction through GCC investments in specialty hospitals, transplantation, and precision medicine, while Africa remains an emerging opportunity where infrastructure, affordability, workforce training, and regulatory harmonization are decisive factors.

Key Group Insights

ASEAN markets are developing through medical tourism, oncology center expansion, and growing interest in regenerative medicine, although regulatory maturity and quality enforcement vary across member states. The GCC is investing in tertiary care, transplant services, national genomics, and precision medicine programs that can support controlled adoption of autologous therapies, particularly where specialized hospitals and international clinical partnerships are expanding.

The European Union provides one of the clearest regulatory structures for advanced therapy medicinal products, supporting cross-border clinical development while maintaining strict manufacturing, pharmacovigilance, traceability, and quality requirements. BRICS countries create scale advantages through large patient populations, expanding clinical trial activity, and growing biomanufacturing capability, while G7 markets remain central for clinical validation, reimbursement evidence, regulatory precedent, and premium launches. NATO countries, while not a healthcare market bloc, overlap with many advanced economies that prioritize supply-chain security, hospital readiness, cold-chain resilience, and biomedical preparedness.

Key Country Insights

The United States leads in commercial autologous immunotherapy adoption, supported by FDA approvals, major cancer centers, accredited cell therapy programs, and a dense manufacturing ecosystem. Canada shows steady uptake through transplant and oncology networks, while Mexico is gaining attention as a regional access hub, provided therapies meet rigorous safety, ethics, and quality standards. Brazil is Latin America's strongest platform for clinical research scale, hematology expertise, and public-private healthcare demand.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced clinical trial capacity with established transplant programs, academic hospitals, and reimbursement scrutiny. Russia has scientific capability and transplant expertise but faces access, funding, and collaboration constraints. China is expanding rapidly in CAR-T research and hospital-based trials, India is building affordability-focused capacity and regulated cell therapy infrastructure, Japan benefits from regenerative medicine policy support and conditional approval mechanisms, Australia offers strong clinical governance and trial networks, and South Korea combines bioprocessing expertise with advanced hospital infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that links clinical outcomes with manufacturability, cost per successful treatment, time to treatment, and long-term safety. Robust registries, real-world evidence programs, standardized adverse event tracking, and harmonized potency assays can strengthen payer confidence and accelerate broader adoption of autologous cell therapies.

Organizations should invest in closed and automated manufacturing, decentralized collection networks, validated cryogenic logistics, digital chain-of-identity and chain-of-custody platforms, and workforce training for cell therapy operations. Strategic partnerships with academic medical centers, certified transplant units, regional manufacturing partners, and qualified logistics providers can reduce implementation risk while improving patient access.

Research Methodology

This executive summary is developed using secondary research from regulatory agencies, peer-reviewed literature, clinical trial registries, clinical practice guidance, hospital adoption patterns, and publicly available information from organizations involved in cell therapy, transplantation, and regenerative medicine. Emphasis is placed on verified market signals, approved therapy pathways, and documented infrastructure trends rather than unsubstantiated claims.

The analytical framework evaluates therapy type, clinical indication, manufacturing model, regulatory pathway, reimbursement environment, regional access, clinical evidence maturity, and technology adoption. Insights are triangulated across clinical evidence, policy developments, commercial approvals, safety requirements, and infrastructure readiness to support decision-making for executives, investors, and healthcare stakeholders.

Conclusion

Autologous stem cell and non-stem cell therapies are advancing from specialized clinical procedures into a more structured personalized medicine market. Their value proposition is strongest where patient-specific biology, durable response, controlled manufacturing, and robust clinical monitoring converge.

Future adoption will depend on scalable production, credible clinical evidence, payer-aligned outcomes, validated quality systems, equitable access models, and responsible integration of artificial intelligence. Organizations that combine scientific rigor with operational excellence will be best positioned to lead the next phase of autologous cell therapy commercialization.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Therapy Type

  • 7.1. Non Stem Cell Therapy
    • 7.1.1. Exosomes
    • 7.1.2. Platelet Rich Plasma
      • 7.1.2.1. Leukocyte Poor Prp
      • 7.1.2.2. Leukocyte Rich Prp
    • 7.1.3. Stromal Vascular Fraction
  • 7.2. Stem Cell Therapy
    • 7.2.1. Hematopoietic Stem Cells
      • 7.2.1.1. Bone Marrow Derived
      • 7.2.1.2. Cord Blood Derived
      • 7.2.1.3. Peripheral Blood Derived
    • 7.2.2. Induced Pluripotent Stem Cells
    • 7.2.3. Mesenchymal Stem Cells
      • 7.2.3.1. Adipose Tissue Derived
      • 7.2.3.2. Bone Marrow Derived
      • 7.2.3.3. Umbilical Cord Derived

8. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication

  • 8.1. Cardiovascular
    • 8.1.1. Ischemic Heart Disease
    • 8.1.2. Myocardial Infarction
    • 8.1.3. Peripheral Artery Disease
  • 8.2. Dermatology
    • 8.2.1. Hair Restoration
    • 8.2.2. Skin Rejuvenation
    • 8.2.3. Wound Healing
  • 8.3. Neurology
    • 8.3.1. Neurodegenerative Disorders
    • 8.3.2. Spinal Cord Injury
    • 8.3.3. Stroke
  • 8.4. Orthopedics
    • 8.4.1. Bone Defects
    • 8.4.2. Cartilage Repair
    • 8.4.3. Osteoarthritis
    • 8.4.4. Tendon Injuries
  • 8.5. Rheumatology
    • 8.5.1. Osteoarthritis
    • 8.5.2. Psoriasis
    • 8.5.3. Rheumatoid Arthritis

9. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Cell Source

  • 9.1. Adipose Tissue
  • 9.2. Bone Marrow
  • 9.3. Peripheral Blood
  • 9.4. Umbilical Cord
    • 9.4.1. Cord Blood
    • 9.4.2. Whartons Jelly

10. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Administration Route

  • 10.1. Intra Articular
    • 10.1.1. Hip Joint
    • 10.1.2. Knee Joint
    • 10.1.3. Shoulder Joint
  • 10.2. Intradermal
  • 10.3. Intramuscular
  • 10.4. Intravenous
    • 10.4.1. Peripheral Infusion
    • 10.4.2. Portal Vein Infusion
  • 10.5. Subcutaneous

11. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Manipulation Level

  • 11.1. Extensive Manipulation
    • 11.1.1. Culture Expanded
    • 11.1.2. Genetic Modification
  • 11.2. Minimal Manipulation

12. Autologous Stem Cell & Non-Stem Cell Therapies Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
    • 12.2.1. Cardiology Clinics
    • 12.2.2. Cosmetic Clinics
    • 12.2.3. Orthopedic Clinics
  • 12.3. Hospitals
  • 12.4. Research Institutes
    • 12.4.1. Academic Institutes
    • 12.4.2. Government Labs
    • 12.4.3. Private Research Labs

13. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Anterogen Co., Ltd.
  • 17.2. Bluebird Bio, Inc.
  • 17.3. Brainstorm Cell Therapeutics, Inc.
  • 17.4. Bristol-Myers Squibb Company
  • 17.5. Cambium Bio Limited
  • 17.6. Castle Creek Biosciences Inc.
  • 17.7. Cytori Therapeutics Inc.
  • 17.8. Dendreon Pharmaceuticals LLC
  • 17.9. Gilead Sciences, Inc.
  • 17.10. Globus Medical Inc
  • 17.11. HCA International Limited
  • 17.12. Hemogenyx Pharmaceuticals PLC
  • 17.13. Hemostemix Inc.
  • 17.14. Jasper Therapeutics, Inc.
  • 17.15. Juventas Therapeutics, Inc.
  • 17.16. Kolon TissueGene, Inc.
  • 17.17. Lisata Therapeutics, Inc.
  • 17.18. Medipost Co., Ltd.
  • 17.19. NOVADIP Biosciences S.A.
  • 17.20. Novartis AG
  • 17.21. Stempeutics Research Pvt. Ltd.
  • 17.22. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CELL SOURCE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY MANIPULATION LEVEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY MANIPULATION LEVEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON STEM CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EXOSOMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EXOSOMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EXOSOMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PLATELET RICH PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PLATELET RICH PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLATELET RICH PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LEUKOCYTE POOR PRP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LEUKOCYTE POOR PRP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LEUKOCYTE POOR PRP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LEUKOCYTE RICH PRP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LEUKOCYTE RICH PRP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LEUKOCYTE RICH PRP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL STROMAL VASCULAR FRACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STROMAL VASCULAR FRACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STROMAL VASCULAR FRACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEMATOPOIETIC STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEMATOPOIETIC STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEMATOPOIETIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BONE MARROW DERIVED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BONE MARROW DERIVED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BONE MARROW DERIVED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CORD BLOOD DERIVED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CORD BLOOD DERIVED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CORD BLOOD DERIVED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PERIPHERAL BLOOD DERIVED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PERIPHERAL BLOOD DERIVED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PERIPHERAL BLOOD DERIVED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADIPOSE TISSUE DERIVED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADIPOSE TISSUE DERIVED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADIPOSE TISSUE DERIVED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BONE MARROW DERIVED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BONE MARROW DERIVED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BONE MARROW DERIVED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL UMBILICAL CORD DERIVED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL UMBILICAL CORD DERIVED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL UMBILICAL CORD DERIVED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MYOCARDIAL INFARCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MYOCARDIAL INFARCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MYOCARDIAL INFARCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PERIPHERAL ARTERY DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PERIPHERAL ARTERY DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PERIPHERAL ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DERMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DERMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DERMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HAIR RESTORATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HAIR RESTORATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HAIR RESTORATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SKIN REJUVENATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SKIN REJUVENATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SKIN REJUVENATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL WOUND HEALING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL WOUND HEALING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL WOUND HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SPINAL CORD INJURY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SPINAL CORD INJURY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SPINAL CORD INJURY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL STROKE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL STROKE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL STROKE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ORTHOPEDICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORTHOPEDICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ORTHOPEDICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BONE DEFECTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BONE DEFECTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BONE DEFECTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TENDON INJURIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TENDON INJURIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TENDON INJURIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RHEUMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RHEUMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RHEUMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ADIPOSE TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ADIPOSE TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ADIPOSE TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BONE MARROW MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BONE MARROW MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BONE MARROW MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL UMBILICAL CORD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL UMBILICAL CORD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL UMBILICAL CORD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CORD BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CORD BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CORD BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL WHARTONS JELLY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL WHARTONS JELLY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL WHARTONS JELLY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL INTRA ARTICULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL INTRA ARTICULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL INTRA ARTICULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL HIP JOINT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HIP JOINT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HIP JOINT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL KNEE JOINT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL KNEE JOINT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL KNEE JOINT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL SHOULDER JOINT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL SHOULDER JOINT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL SHOULDER JOINT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL PERIPHERAL INFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL PERIPHERAL INFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL PERIPHERAL INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL PORTAL VEIN INFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL PORTAL VEIN INFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL PORTAL VEIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY MANIPULATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL EXTENSIVE MANIPULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL EXTENSIVE MANIPULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL EXTENSIVE MANIPULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CULTURE EXPANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CULTURE EXPANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CULTURE EXPANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL GENETIC MODIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL GENETIC MODIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL GENETIC MODIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL MINIMAL MANIPULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL MINIMAL MANIPULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL MINIMAL MANIPULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CARDIOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CARDIOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CARDIOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL COSMETIC CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL COSMETIC CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL COSMETIC CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL ORTHOPEDIC CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL ORTHOPEDIC CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL ORTHOPEDIC CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL GOVERNMENT LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL GOVERNMENT LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL GOVERNMENT LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL PRIVATE RESEARCH LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL PRIVATE RESEARCH LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL PRIVATE RESEARCH LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY NON STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY PLATELET RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY RHEUMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY UMBILICAL CORD, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INTRA ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY MANIPULATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY EXTENSIVE MANIPULATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY NON STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY PLATELET RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY RHEUMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY UMBILICAL CORD, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INTRA ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY MANIPULATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY EXTENSIVE MANIPULATION, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY NON STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY PLATELET RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY RHEUMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY UMBILICAL CORD, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INTRA ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY MANIPULATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY EXTENSIVE MANIPULATION, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY NON STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY PLATELET RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY RHEUMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY UMBILICAL CORD, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INTRA ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY MANIPULATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY EXTENSIVE MANIPULATION, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 302. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY NON STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY PLATELET RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 306. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 308. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 310. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 312. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 314. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY RHEUMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 316. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY UMBILICAL CORD, 2018-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 318. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INTRA ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 320. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY MANIPULATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY EXTENSIVE MANIPULATION, 2018-2032 (USD MILLION)
  • TABLE 322. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 324. MIDDLE EAST AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 325. AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY NON STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 328. AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY PLATELET RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 329. AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 330. AFRICA AUTOLOGOUS STEM CELL & NON-STE